NCT05085574View on ClinicalTrials.gov

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 7, 2023

Primary Completion Date

February 7, 2023

Study Completion Date

February 7, 2023

Conditions
2019 Novel Coronavirus Disease2019 Novel Coronavirus Infection2019-nCoV Disease2019-nCoV InfectionCOVID-19 PandemicCOVID-19 Virus DiseaseCOVID-19 Virus InfectionCovid19Coronavirus Disease 2019SARS-CoV-2 InfectionSARS-CoV-2 Acute Respiratory DiseaseCOVID-19
Interventions
DRUG

Famotidine

80 mg tablet, QID for 14 days

DRUG

Celecoxib

400 mg (initial dose), then 200 mg capsule, BID for 5 days

DRUG

Placebo

tablet, QID for 14 days; capsule, BID for 5 days

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Leidos Life Sciences

INDUSTRY

NCT05085574 - Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) | Biotech Hunter | Biotech Hunter